[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-367228-105":59,"doc-detail-367228-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","integrated-pharmacogenetic-signature-for-the-prediction-of-prostatic-neoplasms-in-men-with-metabolic-disorders","Integrated Pharmacogenetic Signature for the Prediction of Prostatic Neoplasms in Men With Metabolic Disorders","","Metabolic dysregulation reshapes oncogenic processes, with CYP450-driven drug handling influenced by genetic variation under epigenetic stress. The study aims to predict susceptibility to prostate neoplasia—focusing on benign prostatic hyperplasia (BPH) and prostate cancer (PCa)—using pharmacoepigenetic and metabolic profiles from Caucasian men. Two independent cohorts totaling 47,389 individuals assessed CYP450 gene risk associations; metabolic ADMET frequencies and miRNA pharmacoepigenetic targeting informed predictive modeling.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/integrated-pharmacogenetic-signature-for-the-prediction-of-prostatic-neoplasms-in-men-with-metabolic-disorders/367228/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/integrated-pharmacogenetic-signature-for-the-prediction-of-prostatic-neoplasms-in-men-with-metabolic-disorders/367228.png","ImageObject",300,407,{"name":92,"@type":93},"Levi","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-27","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",18,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"What was the goal of the study?","Question",{"text":113,"@type":114},"To predict susceptibility to prostate neoplasia, specifically BPH and prostate cancer, using pharmacoepigenetic and metabolic profiles in Caucasian men.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"How were genetic and metabolic factors evaluated?",{"text":118,"@type":114},"Two independent cohorts totaling 47,389 individuals were analyzed for risk associations of CYP450 genes, with statistical evaluation of metabolic profiles and calculation of ADMET property frequencies.",{"name":120,"@type":111,"acceptedAnswer":121},"Which genetic polymorphism and miRNAs were highlighted in the results?",{"text":122,"@type":114},"CYP3A4*1B was identified as the most related pharmacogenetic polymorphism for prostate cancer susceptibility, and miRNA-200c-3p and miRNA-27b-3p were linked to CYP3A4 targeting and prostate cancer predisposition.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},367228,1790197001,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":140,"language":141,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":67,"update_tm":145,"read_time":146,"preview_page_count":19,"preview_urls":147},7971461740909,"https://ap-avatar.wpscdn.com/davatar_155a257f0dc6eb9ab79c44ca47cae57d","doi: 10.21873/cgp.20502  \nIntegrated Pharmacogenetic Signature for the Prediction of Prostatic Neoplasms in Men With Metabolic Disorders  \nMARIA PAGONI1, VASILEIOS L. ZOGOPOULOS2, STAVROS KONTOGIANNIS3, ANNIA TSOLAKOU1, VASSILIOS ZOUMPOURLIS4, GEORGE TH. TSANGARIS5, ELEFTHERIOS FOKAEFS3,  \nIOANNIS MICHALOPOULOS2, ARISTIDIS M. TSATSAKIS6 and NIKOLAOS DRAKOULIS1  \n1 Research Group of Clinical Pharmacology and Pharmacogenomics, Faculty of Pharmacy, School of Health Sciences, National and Kapodistrian University of Athens, Athens, Greece; 2Centre of Systems Biology, Biomedical Research Foundation, Academy of Athens, Athens, Greece;  \n3 Department of Urology, Patras University Hospital, Patras, Greece;  \n4 National Hellenic Research Foundation, Athens, Greece;  \n5 Proteomics Research Unit, Biomedical Research Foundation, Academy of Athens, Athens, Greece;  \n6 Department of Forensic Sciences and Toxicology, Faculty of Medicine, University of Crete, Heraklion, Greece  \nAbstract  \nBackground/Aim: Oncogenic processes are delineated by metabolic dysregulation. Drug likeness ispharmacokinetically tested through the CYP450 enzymatic system, whose genetic aberrations under epigenetic stress could shift male organisms into prostate cancer pathways. Our objective was to predict the susceptibility to prostate neoplasia, focused on benign prostatic hyperplasia (BPH) and prostate cancer (PCa), based on the pharmacoepigenetic and the metabolic profile of Caucasians.  \nMaterials and Methods: Two independent cohorts of 47,389 individuals in total were assessed to find risk associations of CYP450 genes with prostatic neoplasia. The metabolic profile of the first cohort was statistically evaluated and frequencies of absorption‑distribution‑metabolism‑excretion‑toxicity (ADMET) properties were calculated. Prediction of miRNA pharmacoepigenetic targeting was performed.  \nResults: We found that prostate cancer and benign prostatic hyperplasia patients of the first cohort shared common cardiometabolic trends. Drug classes C08CA, C09AA, C09CA, C10AA, C10AX of the cardiovascular, and G04CA, G04CB of the genitourinary systems, were associated with increased prostate cancer risk, while C03CA and N06AB of the cardiovascular and nervous systems were associated with low‑risk for PCa. CYP3A4*1B was the most related pharmacogenetic polymorphism associated with prostate cancer susceptibility. miRNA‑200c‑3p and miRNA‑27b‑3p seem to be associated with CYP3A4 targeting and prostate cancer predisposition. Metabolomic analysis indicated  \n✉  \nMaria Pagoni, Research Group of Clinical Pharmacology and Pharmacogenomics, Faculty of Pharmacy, School of Health Sciences, National and Kapodistrian University of Athens, 15771 Athens, Greece. Tel: +30 2107274149, e‑mail: maria.pagoni@pharm.uoa.gr and George Th.  \nTsangaris, Proteomics Research Unit, Biomedical Research Foundation, Academy of Athens, Soranou Efessiou 4, 11527 Athens, Greece. Tel: +30  \n2106597075, e‑[mail: gthtsangaris@bioacademy.gr](mail: gthtsangaris@bioacademy.gr)  \nReceived December 20, 2024 | Revised January 14, 2025 | Accepted January 16, 2025  \nThis is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.  \n©2025 The Author(s) . Anticancer Research is published by the International Institute of Anticancer Research.  \nthat 11β‑OHT, 2β‑OHT, 15β‑OHT, 2α‑OHT and 6β‑OHT had a high risk, and 16α‑OHT, and 16β‑OHT had an intermediate disease‑risk.  \nConclusion: These findings constitute a novel integrated signature for prostate cancer susceptibility. Further studies are required to assess their predictive value more fully.  \nKeywords: Pharmacogenetics, epigenetics, metabolomics, prostatic neoplasia, PCa, BPH, diabetes, dislipidemia, hypertension, steroid hormone pathway, FoxO signaling pathway, p53 signaling pathway, estrogen signaling pathway, CYP3A4, miRNAs.  \nIntroduction ","cbCaihxnputQEF5p","https://ap.wps.com/l/cbCaihxnputQEF5p","pdf",2589386,21,"English","# Abstract\n# Background/Aim\n# Materials and Methods\n## Cohorts and Risk Associations\n## Metabolic and ADMET Profiling\n## miRNA Pharmacoepigenetic Targeting\n# Results\n# Conclusion\n# Keywords\n# Introduction","[{\"question\":\"What was the goal of the study?\",\"answer\":\"To predict susceptibility to prostate neoplasia, specifically BPH and prostate cancer, using pharmacoepigenetic and metabolic profiles in Caucasian men.\"},{\"question\":\"How were genetic and metabolic factors evaluated?\",\"answer\":\"Two independent cohorts totaling 47,389 individuals were analyzed for risk associations of CYP450 genes, with statistical evaluation of metabolic profiles and calculation of ADMET property frequencies.\"},{\"question\":\"Which genetic polymorphism and miRNAs were highlighted in the results?\",\"answer\":\"CYP3A4*1B was identified as the most related pharmacogenetic polymorphism for prostate cancer susceptibility, and miRNA-200c-3p and miRNA-27b-3p were linked to CYP3A4 targeting and prostate cancer predisposition.\"}]","Integrated Pharmacogenetic Signature for the Prediction of Prostatic Neoplasms in Men With Metabolic Disorders | PDF",1790169777,53,[148,152,156,160],{"page_no":8,"url":149,"width":150,"height":151},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/79014f0a1942d8cd6c9251da65cc0ca7.webp",983,1301,{"page_no":14,"url":153,"width":154,"height":155},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a090e1847b4f79505afc663c2b41ab27.webp",982,1299,{"page_no":81,"url":157,"width":158,"height":159},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d0abf24f2557a561e974ca853dfb274b.webp",981,1298,{"page_no":19,"url":161,"width":162,"height":163},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a3662d5bfc272a3c3cd898cf455965d3.webp",980,1297]